Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets
Open accessAbstract
INTRODUCTION: Predictive survival modeling offers systematic tools for clinical decision-making and individualized tailoring of treatment strategies to improve patient outcomes while reducing overall healthcare costs. In 2015, a number of machine learning and statistical models were benchmarked in the DREAM 9.5 Prostate Cancer Challenge, based on open clinical trial data for metastatic castration resistant prostate cancer (mCRPC). However, applying these models into clinical practice poses a practical challenge due to the inclusion of a large number of model variables, some of which are not routinely monitored or are expensive to measure. OBJECTIVES: To develop cost-specified variable selection algorithms for constructing cost-effective prognostic models of overall survival that still preserve sufficient model performance for clinical decision making. METHODS: Penalized Cox regression models were used for the survival prediction. For the variable selection, we implemented two algorithms: (i) LASSO regularization approach; and (ii) a greedy cost-specified variable selection algorithm. The models were compared in three cohorts of mCRPC patients from randomized clinical trials (RCT), as well as in a real-world cohort (RWC) of advanced prostate cancer patients treated at the Turku University Hospital. Hospital laboratory expenses were utilized as a reference for computing the costs of introducing new variables into the models. RESULTS: Compared to measuring the full set of clinical variables, economic costs could be reduced by half without a significant loss of model performance. The greedy algorithm outperformed the LASSO-based variable selection with the lowest tested budgets. The overall top performance was higher with the LASSO algorithm. CONCLUSION: The cost-specified variable selection offers significant budget optimization capability for the real-world survival prediction without compromising the predictive power of the model.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Murtojärvi et al. demonstrated significant cost reductions in oncology through AI-driven feature selection.
“Murtojärvi et al.22, for instance, demonstrated significant cost reductions in oncology through AI-driven feature selection”
From Systematic review of cost effectiveness and budget impact of artificial intelligence in healthcare (2025) · cites this paper as Murtojärvi et al.22
The citation lists haven’t been fetched yet
References 35 · Cited by 14
- Authors
- Murtojärvi, M., Halkola, A. S., Airola, A., Laajala, T. D., Mirtti, T., Aittokallio, T., & Pahikkala, T.
- Affiliations
- University of Turku (FI)
- University of Helsinki (FI)
- Corresponding author
- Murtojärvi, Mika
- Venue
- International Journal of Medical Informatics
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 133
- Pages
- 104014
- ISSN
- 1386-5056 (ISSN-L)
- OpenAlex
- W2988487920
- Cited by
- 14
- References
- 35
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 2 · 2022: 1 · 2021: 6 · 2020: 2
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- International Journal of Medical Informatics (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UTUPub (University of Turku) (submittedVersion)
- UTUPub (University of Turku) (submittedVersion, cc-by-nc-nd)
- Työväentutkimus Vuosikirja (submittedVersion)
- Funders
- Suomen Kulttuurirahasto
- Syöpäjärjestöt
- Suomen Lääketieteen Säätiö
- Sigrid Juséliuksen Säätiö
- Helsingin ja Uudenmaan Sairaanhoitopiiri
- Turun Yliopisto
- Academy of Finland
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods and Inference
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Keywords
- metastatic castration-resistant prostate cancer, overall survival prediction, feature selection, LASSO regularization, hospital laboratory costs, clinical trial data, healthcare cost reduction
- MeSH terms
- Clinical Decision-Making, Aged, Aged, 80 and over, Algorithms, Cost-Benefit Analysis, Hospitals, Humans, Male, Prognosis, Prostatic Neoplasms, Registries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review